Search results for "ta3121"

showing 10 items of 65 documents

Clinical phenotypes and comorbidity in European sleep apnoea patients

2016

PubMed ID: 27701416

MalePulmonologyPhysiologyApneamedicine.medical_treatmentlcsh:MedicineComorbidityPolysomnographyCardiovascular MedicineMedicine (all); Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)THERAPYBody Mass Index0302 clinical medicineRisk FactorsPositive airway pressureMedicine and Health SciencesInsomniaMedicineProspective StudiesContinuous positive airway pressurelcsh:ScienceProspective cohort studyClinical NeurophysiologyAged 80 and overHypersomniaMultidisciplinarymedicine.diagnostic_testMedicine (all)Sleep apneaMiddle AgedDEPRESSIONPREVALENCEComputingMilieux_MANAGEMENTOFCOMPUTINGANDINFORMATIONSYSTEMSPhenotypeNeurologyPhysiological ParametersCardiovascular DiseasesCARDIOVASCULAR-DISEASEFemaleInformationSystems_MISCELLANEOUSmedicine.symptomEngineering sciences. TechnologyHypopneaINSOMNIA SYMPTOMSResearch ArticleAdultmedicine.medical_specialtyInsomniaSleep ApneaAdolescentPOSITIVE AIRWAY PRESSUREPolysomnographySettore MED/10 - Malattie Dell'Apparato RespiratorioWhite PeopleYoung Adult03 medical and health sciencesSleep Apnea SyndromesDAYTIMEstomatognathic systemComorbiditatDiagnostic MedicineInternal medicinemental disordersHumansCOMMONAgedHYPOPNEABiochemistry Genetics and Molecular Biology (all)HYPERTENSIONbusiness.industrylcsh:RBody WeightComputerSystemsOrganization_COMPUTER-COMMUNICATIONNETWORKSBiology and Life Sciencesta3121medicine.diseaseComorbidityDyssomniasrespiratory tract diseasesnervous system diseasesComputingMethodologies_PATTERNRECOGNITIONAgricultural and Biological Sciences (all)030228 respiratory systemPhysical therapylcsh:QSleep DisordersPhysiological ProcessesSleepbusiness030217 neurology & neurosurgeryFollow-Up Studies
researchProduct

Effect of hydrolyzed infant formula vs conventional formula on risk of type 1 diabetes the TRIGR randomized clinical trial

2018

IMPORTANCE Early exposure to complex dietary proteins may increase the risk of type 1 diabetes in children with genetic disease susceptibility. There are no intact proteins in extensively hydrolyzed formulas. OBJECTIVE To test the hypothesis that weaning to an extensively hydrolyzed formula decreases the cumulative incidence of type 1 diabetes in young children. DESIGN, SETTING, AND PARTICIPANTS An international double-blind randomized clinical trial of 2159 infants with human leukocyte antigen-conferred disease susceptibility and a first-degree relative with type 1 diabetes recruited from May 2002 to January 2007 in 78 study centers in 15 countries; 1081 were randomized to be weaned to the…

MaleRiskmedicine.medical_specialtyCaseinBreastfeeding030209 endocrinology & metabolism610 Medicine & health2700 General MedicineEndocrinology and DiabetesDisease-Free Survivallaw.inventionFollow-Up StudieNutrition Policy03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodSDG 3 - Good Health and Well-beinglawInternal medicineDiabetes mellitusmedicineHumansCumulative incidence030212 general & internal medicineChildInfant Nutritional Physiological PhenomenaOriginal Investigation2. Zero hungerType 1 diabetesbusiness.industryHazard ratioAbsolute risk reductionInfant NewbornCaseinsGeneral Medicineta3121medicine.diseaseInfant Formula3. Good healthDiabetes Mellitus Type 1Infant formula10036 Medical ClinicEndokrinologi och diabetesFemalebusinessHumanFollow-Up Studies
researchProduct

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

2017

Item does not contain fulltext BACKGROUND: Bococizumab is a humanized monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9) and reduces levels of low-density lipoprotein (LDL) cholesterol. We sought to evaluate the efficacy of bococizumab in patients at high cardiovascular risk. METHODS: In two parallel, multinational trials with different entry criteria for LDL cholesterol levels, we randomly assigned the 27,438 patients in the combined trials to receive bococizumab (at a dose of 150 mg) subcutaneously every 2 weeks or placebo. The primary end point was nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina requiring urgent re…

MaleSTATIN THERAPYAnticholesteremic Agents/adverse effectsAntibodieVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Injections Subcutaneous/adverse effects030204 cardiovascular system & hematologyBococizumablaw.inventionPCSK90302 clinical medicineRandomized controlled triallawRisk FactorsGENETIC-VARIANTSCardiovascular DiseaseMonoclonalAnticholesteremic Agent030212 general & internal medicineMyocardial infarctionTreatment FailureHumanizedProprotein Convertase 9/antagonists & inhibitorsMedicine(all)Antibodies; Antibodies Monoclonal Humanized; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypercholesterolemia; Injections Subcutaneous; Lipids; Male; Middle Aged; Proprotein Convertase 9; Risk Factors; Treatment Failure; Medicine (all)Anticholesteremic AgentsMedicine (all)PCSK9 InhibitorsAntibodies; antibodies monoclonal humanized; anticholesteremic agents; cardiovascular diseases; cholesterol LDL; double-blind method; female; follow-up studies; humans; hypercholesterolemia; injections subcutaneous; lipids; male; middle aged; proprotein convertase 9; risk factors; treatment failure; medicine (all)Vascular damage Radboud Institute for Molecular Life Sciences [Radboudumc 16]General MedicineLipidMiddle AgedLipids3. Good healthLDL/bloodMulticenter StudyCholesterolTRIALSCholesterol LDL/bloodCardiovascular DiseasesAntibodies Monoclonal Humanized/adverse effectsanticholesteremic agentsRandomized Controlled Trialsubcutaneouslipids (amino acids peptides and proteins)FemaleProprotein Convertase 9Cardiovascular Diseases/prevention & controlREDUCING LIPIDSHumanmedicine.medical_specialtyanimal structuresInjections SubcutaneousHypercholesterolemiaHypercholesterolemia/drug therapyPlaceboAntibodies Monoclonal HumanizedInjections SubcutaneouAntibodiesLDLInjectionsFollow-Up StudielipidsEVENTS03 medical and health sciencesantibodies monoclonal humanizedDouble-Blind MethodInternal medicinemedicineJournal ArticleHumansComparative StudyMETAANALYSISAlirocumabbusiness.industryUnstable anginaLipids/bloodPCSK9Risk FactorfungiAntibodies/bloodCholesterol LDLta3121medicine.diseaseSurgerycardiovascular diseasesEvolocumabREDUCTIONHumanized/adverse effectsSubcutaneous/adverse effectsbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up Studies
researchProduct

2013 ESH/ESC Guidelines for the management of arterial hypertension

2013

Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present guidelines differ in many respects from the previous ones. Some of the most important differences are listed below: 1. Epidemiological data on hypertension and BP control in Europe. 2. Strengthening of the prognostic value of home blood pressure monitoring (HBPM) and of its role for diagnosis and management of hypertension, next to ambulatory blood pressure monitoring (ABPM). 3. Update of the prognostic significance of night-time BP, white-coat hypertension and masked hypertension. 4. Re-emphasis on integration of BP, cardiovascular (CV) risk factors, asymptomatic organ damage (OD) and clinica…

Maleblood pressure measurementPhysiologyEnfermedad cardiovascularWhite coat hypertensionLeft ventricular hypertrophyEpidemiologyfollow-upguidelinesblood pressureGeneral MedicineMiddle AgedEuropeOrgan damageRenal sympathetic denervationCardiologyFemaleCardiology and Cardiovascular MedicineRisk assessmentAdultcardiovascular risklifestylemedicine.medical_specialtyhypertensionAmbulatory blood pressureorgan damagecardiovascular complicationsCardiologíaPrehypertensionantihypertensive treatmentYoung AdultDevice therapyInternal medicineHipertensiónInternal MedicinemedicineHumansdevice therapyLife StyleAntihypertensive AgentsSistema cardiovascularAgedTask forcebusiness.industryta3121medicine.diseaseMasked HypertensionBlood pressureIntima-media thicknessbusinessJournal of Hypertension
researchProduct

Global electrical heterogeneity as a predictor of cardiovascular mortality in men and women

2018

Aims The aim of this study was to investigate the contribution of depolarization and repolarization abnormalities, specially abnormalities in global electrical heterogeneity of heart in cardiovascular disease (CVD) and all-cause mortality. Methods and results Eight hundred and forty men and 911 women, average age of 63 years participated in this study with average follow-up was 14 years. Six electrocardiogram/vector electrocardiogram (ECG/VECG) markers QRS-duration, QTc-interval, QRST-angle, sum of absolute QRST integral (SAI QRST), T-wave roundness, and TV1-amplitude were estimated from VECG measurements. Hazard ratios (HRs) for CVD events (164 deaths) and all-cause mortality (383 deaths) …

Malekuolleisuusmedicine.medical_specialtyglobal electrical heterogeneityVectorcardiography030204 cardiovascular system & hematologyelectrocardiogramQT intervalRESTING HEART RATERisk Assessment03 medical and health sciencesElectrocardiography0302 clinical medicineSex FactorsRisk Factorscardiovascular diseasecardiovascular mortalityQRST-anglePhysiology (medical)Internal medicinemedicineMale populationRepolarizationHumanscardiovascular diseases030212 general & internal medicineEKGFinlandCardiovascular mortalitybusiness.industryHazard ratiota3142riskitekijätMiddle Agedta3121Confidence intervalElectrophysiological PhenomenaCardiovascular DiseasesRisk stratificationCardiologysydän- ja verisuonitauditFemaleseurantatutkimusCardiology and Cardiovascular MedicinebusinessEuropace
researchProduct

Increased insulin-stimulated glucose uptake in both leg and arm muscles after sprint interval and moderate-intensity training in subjects with type 2…

2017

We investigated the effects of sprint interval training (SIT) and moderate-intensity continuous training (MICT) on glucose uptake (GU) during hyperinsulinemic euglycemic clamp and fatty acid uptake (FAU) at fasting state in thigh and arm muscles in subjects with type 2 diabetes (T2D) or prediabetes. Twenty-six patients (age 49, SD 4; 10 women) were randomly assigned into two groups: SIT (n=13) and MICT (n=13). The exercise in the SIT group consisted of 4–6×30 s of all-out cycling with 4- minute recovery and in the MICT group 40- to 60- minute cycling at 60% of VO2peak. Both groups completed six training sessions within two weeks. GU and FAU were measured before and after the intervention wi…

Malemedicine.medical_specialty030209 endocrinology & metabolismPhysical Therapy Sports Therapy and RehabilitationType 2 diabetesThighBicepsInterval trainingPrediabetic State03 medical and health sciences0302 clinical medicineInsulin resistanceOxygen ConsumptionInternal medicinemedicineHumansInsulinOrthopedics and Sports MedicinePrediabetesta315Muscle SkeletalExerciseLegbusiness.industrySkeletal muscle030229 sport sciencesta3121Middle Agedmedicine.diseasemedicine.anatomical_structureGlucoseSprintDiabetes Mellitus Type 2CardiologyPhysical therapyArmBody CompositionGlucose Clamp TechniqueCarbohydrate MetabolismFemalebusinessPhysical Conditioning HumanScandinavian journal of medicinescience in sports
researchProduct

Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial …

2015

BACKGROUND: Cardiovascular (CV) disease is the leading cause of morbidity and mortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.METHODS: ELIXA (www.clinicaltrials.gov no. NCT01147250) is a randomized, double-blind, placebo-controlled, parallel-group, multicenter study of lixisenatide in patients with T2DM and a recent ACS event. The primary aim is to evaluate the effects of lixisenatide on CV morbidity and mortality in a population …

Malemedicine.medical_specialtyAcute coronary syndromePopulationLIXisenatide610 Medicine & healthHypoglycemiaPlacebop38 Mitogen-Activated Protein Kinases11171 Cardiocentro Ticino2705 Cardiology and Cardiovascular Medicinelaw.inventionSettore MED/13 - EndocrinologiaAcute Coronary Syndrome; Aged; Cardiovascular Diseases; Double-Blind Method; Female; Glucagon-Like Peptide 1; Humans; Male; Middle Aged; Peptides; Placebos; Protein Kinase Inhibitors; Research Design; p38 Mitogen-Activated Protein Kinases; Cardiology and Cardiovascular MedicinePlacebosLixisenatidechemistry.chemical_compoundRandomized controlled trialDouble-Blind MethodlawGlucagon-Like Peptide 1Internal medicineJournal ArticlemedicineHumansComparative StudyMyocardial infarctionAcute Coronary SyndromeeducationProtein Kinase InhibitorsAgededucation.field_of_studybusiness.industryUnstable anginaResearch Support Non-U.S. Gov'tta3121Middle Agedmedicine.diseaseSurgeryMulticenter StudychemistryCardiovascular DiseasesResearch DesignRandomized Controlled TrialCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPeptides
researchProduct

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes

2013

Item does not contain fulltext BACKGROUND: Although P2Y12 antagonists are effective in patients with non-ST-segment elevation (NSTE) acute coronary syndromes, the effect of the timing of administration--before or after coronary angiography--is not known. We evaluated the effect of administering the P2Y12 antagonist prasugrel at the time of diagnosis versus administering it after the coronary angiography if percutaneous coronary intervention (PCI) was indicated. METHODS: We enrolled 4033 patients with NSTE acute coronary syndromes and a positive troponin level who were scheduled to undergo coronary angiography within 2 to 48 hours after randomization. Patients were randomly assigned to recei…

Malemedicine.medical_specialtyAcute coronary syndromePrasugrelmedicine.medical_treatmentPremedicationMyocardial InfarctionHemorrhageThiophenesCoronary AngiographyPiperazinesPercutaneous Coronary InterventionDouble-Blind MethodInternal medicinemedicineHumansMyocardial infarctionAcute Coronary SyndromeCoronary Artery BypassAgedCardiovascular diseases [NCEBP 14]business.industryMedicine (all)Hazard ratioAcute Coronary Syndrome; Aged; Coronary Artery Bypass; Double-Blind Method; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Piperazines; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Coronary Angiography; Premedication; Medicine (all)Percutaneous coronary interventionGeneral MedicineThrombolysisMiddle Agedta3121medicine.diseaseConventional PCICardiologyPurinergic P2Y Receptor AntagonistsFemalebusinessPrasugrel HydrochlorideTIMImedicine.drug
researchProduct

Common Genetic Variation in Relation to Brachial Vascular Dimensions and Flow-Mediated Vasodilation

2019

Common Genetic Variation in Relation to Brachial Vascular Dimensions and Flow-Mediated Vasodilation

Malemedicine.medical_specialtyBrachial ArteryVasodilationGenome-wide association studyPolymorphism Single NucleotideArticleInternal medicinemedicine.arteryGenetic variationmedicineHumanscardiovascular diseasesBrachial arteryCation Transport ProteinsUltrasonographybusiness.industryGenetic VariationGeneral MedicineMethyltransferasesta3121Middle Agedbody regionsVasodilationInsulin-Like Growth Factor Binding Protein 3PhenotypeCardiovascular DiseasesGenetic Locicardiovascular systemCardiologyMedical geneticsDilation (morphology)Femalebusinesscirculatory and respiratory physiologyFlow-Mediated Vasodilation
researchProduct

The associations of cardiorespiratory fitness, adiposity and sports participation with arterial stiffness in youth with chronic diseases or physical …

2017

Article

Malemedicine.medical_specialtyobesityPhysical disabilityAdolescentEpidemiologyHealth Status030204 cardiovascular system & hematologyPulse Wave AnalysisBody Mass Index03 medical and health sciences0302 clinical medicineOxygen ConsumptionVascular StiffnessSurveys and QuestionnairesmedicineJournal ArticleHumans030212 general & internal medicineChildta315AdiposityOriginal Scientific Paperyouthcardiorespiratory fitnessexercisebusiness.industryPreventionAge FactorsCardiorespiratory fitnessta3121medicine.diseaseObesityDisabled ChildrenChronic diseaseCross-Sectional Studiesarterial stiffnessArterial stiffnessPhysical therapyExercise TestnuoruuslihavuusFemaleWaist CircumferenceCardiology and Cardiovascular Medicinebusinesshuman activitieschronic diseaseSportsEuropean Journal of Preventive Cardiology
researchProduct